APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sickle Cell Anemia Therapeutics

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Selected research

Market Structure

Global Sickle Cell Anemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025192 pages

Choose your research edition.

Industry ResearchSickle Cell Anemia Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Sickle Cell Anemia Therapeutics Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Sickle Cell Anemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sickle Cell Anemia Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Sickle Cell Anemia Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.

Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.

Read the full market overview

In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.

Report Includes

This report provides an overview of the global Sickle Cell Anemia Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sickle Cell Anemia Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sickle Cell Anemia Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Sickle Cell Anemia Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Sickle Cell Anemia Therapeutics Segment by Company

Emmaus Medical

Addmedica

Gamida Cell

GlycoMimetics

Pfizer

Novartis

Global Blood Therapeutics

Micelle BioPharma

Bluebird Bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo Biosciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Sickle Cell Anemia Therapeutics Segment by Type

Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant

Sickle Cell Anemia Therapeutics Segment by Application

Child

Adult

Sickle Cell Anemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Anemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Anemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Anemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Sickle Cell Anemia Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sickle Cell Anemia Therapeutics industry.

Chapter 3: Detailed analysis of Sickle Cell Anemia Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sickle Cell Anemia Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Blood Transfusion Table 3. Key Players of Pharmacotherapy Table 4. Key Players of Bone Marrow Transplant Table 4. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Child Table 6. Key Players of Adult Table 7. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Sickle Cell Anemia Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Sickle Cell Anemia Therapeutics Market Share by Region (2021-2026) Table 10. Global Sickle Cell Anemia Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Sickle Cell Anemia Therapeutics Market Share by Region (2027-2032) Table 12. Sickle Cell Anemia Therapeutics Industry Trends Table 13. Sickle Cell Anemia Therapeutics Industry Drivers Table 14. Sickle Cell Anemia Therapeutics Industry Opportunities and Challenges Table 15. Sickle Cell Anemia Therapeutics Industry Restraints Table 16. Global Sickle Cell Anemia Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Company (2021-2026) Table 18. Global Sickle Cell Anemia Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Sickle Cell Anemia Therapeutics Key Company Head Office and Area Served Table 20. Global Sickle Cell Anemia Therapeutics Company, Product Type & Application Table 21. Global Sickle Cell Anemia Therapeutics Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Sickle Cell Anemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Sickle Cell Anemia Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Global Sickle Cell Anemia Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2021-2026) Table 33. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2027-2032) Table 34. Emmaus Medical Company Information Table 35. Emmaus Medical Business Overview Table 36. Emmaus Medical Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio Table 38. Emmaus Medical Recent Development Table 39. Addmedica Company Information Table 40. Addmedica Business Overview Table 41. Addmedica Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Addmedica Sickle Cell Anemia Therapeutics Product Portfolio Table 43. Addmedica Recent Development Table 44. Gamida Cell Company Information Table 45. Gamida Cell Business Overview Table 46. Gamida Cell Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio Table 48. Gamida Cell Recent Development Table 49. GlycoMimetics Company Information Table 50. GlycoMimetics Business Overview Table 51. GlycoMimetics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio Table 53. GlycoMimetics Recent Development Table 54. Pfizer Company Information Table 55. Pfizer Business Overview Table 56. Pfizer Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Pfizer Sickle Cell Anemia Therapeutics Product Portfolio Table 58. Pfizer Recent Development Table 59. Novartis Company Information Table 60. Novartis Business Overview Table 61. Novartis Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Novartis Sickle Cell Anemia Therapeutics Product Portfolio Table 63. Novartis Recent Development Table 64. Global Blood Therapeutics Company Information Table 65. Global Blood Therapeutics Business Overview Table 66. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio Table 68. Global Blood Therapeutics Recent Development Table 69. Micelle BioPharma Company Information Table 70. Micelle BioPharma Business Overview Table 71. Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio Table 73. Micelle BioPharma Recent Development Table 74. Bluebird Bio Company Information Table 75. Bluebird Bio Business Overview Table 76. Bluebird Bio Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio Table 78. Bluebird Bio Recent Development Table 79. Prolong Pharmaceuticals Company Information Table 80. Prolong Pharmaceuticals Business Overview Table 81. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio Table 83. Prolong Pharmaceuticals Recent Development Table 84. Modus Therapeutics Company Information Table 85. Modus Therapeutics Business Overview Table 86. Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio Table 88. Modus Therapeutics Recent Development Table 89. Sangamo Biosciences Company Information Table 90. Sangamo Biosciences Business Overview Table 91. Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio Table 93. Sangamo Biosciences Recent Development Table 94. Bioverativ Company Information Table 95. Bioverativ Business Overview Table 96. Bioverativ Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio Table 98. Bioverativ Recent Development Table 99. Imara Company Information Table 100. Imara Business Overview Table 101. Imara Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. Imara Sickle Cell Anemia Therapeutics Product Portfolio Table 103. Imara Recent Development Table 104. Ironwood Pharmaceuticals Company Information Table 105. Ironwood Pharmaceuticals Business Overview Table 106. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio Table 108. Ironwood Pharmaceuticals Recent Development Table 109. North America Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 110. North America Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 111. North America Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 112. North America Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 113. North America Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026) Table 115. North America Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032) Table 116. Europe Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 117. Europe Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 118. Europe Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 119. Europe Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 120. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026) Table 122. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032) Table 123. China Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 124. China Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 125. China Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 126. China Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 127. Asia Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 128. Asia Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 129. Asia Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 130. Asia Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 131. Asia Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Asia Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026) Table 133. Asia Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032) Table 134. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 135. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 136. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 137. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 138. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026) Table 140. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032) Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Sickle Cell Anemia Therapeutics Product Image Figure 2. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Sickle Cell Anemia Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. Blood Transfusion Image Figure 5. Pharmacotherapy Image Figure 6. Bone Marrow Transplant Image Figure 7. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Sickle Cell Anemia Therapeutics Market Share by Application: 2025 VS 2032 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Sickle Cell Anemia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 13. Global Sickle Cell Anemia Therapeutics Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Sickle Cell Anemia Therapeutics Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Sickle Cell Anemia Therapeutics Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Sickle Cell Anemia Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global Sickle Cell Anemia Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 23. North America Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032) Figure 24. North America Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032) Figure 25. North America Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032) Figure 26. United States Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 27. Canada Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 29. Europe Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 30. Europe Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032) Figure 31. Europe Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032) Figure 32. Europe Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032) Figure 33. Germany Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 34. France Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 36. Italy Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 37. Russia Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. China Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. China Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032) Figure 41. China Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032) Figure 42. Asia Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 43. Asia Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032) Figure 44. Asia Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032) Figure 45. Asia Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032) Figure 46. Japan Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 50. India Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. Australia Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032) Figure 56. Brazil Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. UAE Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. Chile Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant
Applications
  • Child
  • Adult
Companies covered
  • Emmaus Medical
  • Addmedica
  • Gamida Cell
  • GlycoMimetics
  • Pfizer
  • Novartis
  • Global Blood Therapeutics
  • Micelle BioPharma
  • Bluebird Bio
  • Prolong Pharmaceuticals
  • Modus Therapeutics
  • Sangamo Biosciences
  • Bioverativ
  • Imara
  • Ironwood Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Blood Transfusion
  5. 1.2.3 Pharmacotherapy
  6. 1.2.4 Bone Marrow Transplant
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Child
  10. 1.3.3 Adult
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Sickle Cell Anemia Therapeutics Growth Trends by Region
  13. 1.5.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Sickle Cell Anemia Therapeutics Market Size by Region (2021-2026)
  15. 1.5.3 Sickle Cell Anemia Therapeutics Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Sickle Cell Anemia Therapeutics Market Dynamics
  1. 2.1 Sickle Cell Anemia Therapeutics Industry Trends
  2. 2.2 Sickle Cell Anemia Therapeutics Industry Drivers
  3. 2.3 Sickle Cell Anemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Sickle Cell Anemia Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Sickle Cell Anemia Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Sickle Cell Anemia Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Sickle Cell Anemia Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Sickle Cell Anemia Therapeutics Company, Product Type & Application
  5. 3.5 Global Sickle Cell Anemia Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Sickle Cell Anemia Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Sickle Cell Anemia Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Sickle Cell Anemia Therapeutics Tier 1, Tier 2, and Tier 3
4 Sickle Cell Anemia Therapeutics Market by Type
  1. 4.1 Global Sickle Cell Anemia Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Sickle Cell Anemia Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Sickle Cell Anemia Therapeutics Market Size Share by Type (2021-2032)
5 Sickle Cell Anemia Therapeutics Market by Application
  1. 5.1 Global Sickle Cell Anemia Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Sickle Cell Anemia Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Sickle Cell Anemia Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Emmaus Medical
  2. 6.1.1 Emmaus Medical Company Information
  3. 6.1.2 Emmaus Medical Business Overview
  4. 6.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio
  6. 6.1.5 Emmaus Medical Recent Developments
  7. 6.2 Addmedica
  8. 6.2.1 Addmedica Company Information
  9. 6.2.2 Addmedica Business Overview
  10. 6.2.3 Addmedica Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Addmedica Sickle Cell Anemia Therapeutics Product Portfolio
  12. 6.2.5 Addmedica Recent Developments
  13. 6.3 Gamida Cell
  14. 6.3.1 Gamida Cell Company Information
  15. 6.3.2 Gamida Cell Business Overview
  16. 6.3.3 Gamida Cell Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio
  18. 6.3.5 Gamida Cell Recent Developments
  19. 6.4 GlycoMimetics
  20. 6.4.1 GlycoMimetics Company Information
  21. 6.4.2 GlycoMimetics Business Overview
  22. 6.4.3 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio
  24. 6.4.5 GlycoMimetics Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Pfizer Sickle Cell Anemia Therapeutics Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Novartis
  32. 6.6.1 Novartis Company Information
  33. 6.6.2 Novartis Business Overview
  34. 6.6.3 Novartis Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Novartis Sickle Cell Anemia Therapeutics Product Portfolio
  36. 6.6.5 Novartis Recent Developments
  37. 6.7 Global Blood Therapeutics
  38. 6.7.1 Global Blood Therapeutics Company Information
  39. 6.7.2 Global Blood Therapeutics Business Overview
  40. 6.7.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
  42. 6.7.5 Global Blood Therapeutics Recent Developments
  43. 6.8 Micelle BioPharma
  44. 6.8.1 Micelle BioPharma Company Information
  45. 6.8.2 Micelle BioPharma Business Overview
  46. 6.8.3 Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio
  48. 6.8.5 Micelle BioPharma Recent Developments
  49. 6.9 Bluebird Bio
  50. 6.9.1 Bluebird Bio Company Information
  51. 6.9.2 Bluebird Bio Business Overview
  52. 6.9.3 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio
  54. 6.9.5 Bluebird Bio Recent Developments
  55. 6.10 Prolong Pharmaceuticals
  56. 6.10.1 Prolong Pharmaceuticals Company Information
  57. 6.10.2 Prolong Pharmaceuticals Business Overview
  58. 6.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
  60. 6.10.5 Prolong Pharmaceuticals Recent Developments
  61. 6.11 Modus Therapeutics
  62. 6.11.1 Modus Therapeutics Company Information
  63. 6.11.2 Modus Therapeutics Business Overview
  64. 6.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
  66. 6.11.5 Modus Therapeutics Recent Developments
  67. 6.12 Sangamo Biosciences
  68. 6.12.1 Sangamo Biosciences Company Information
  69. 6.12.2 Sangamo Biosciences Business Overview
  70. 6.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio
  72. 6.12.5 Sangamo Biosciences Recent Developments
  73. 6.13 Bioverativ
  74. 6.13.1 Bioverativ Company Information
  75. 6.13.2 Bioverativ Business Overview
  76. 6.13.3 Bioverativ Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio
  78. 6.13.5 Bioverativ Recent Developments
  79. 6.14 Imara
  80. 6.14.1 Imara Company Information
  81. 6.14.2 Imara Business Overview
  82. 6.14.3 Imara Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Imara Sickle Cell Anemia Therapeutics Product Portfolio
  84. 6.14.5 Imara Recent Developments
  85. 6.15 Ironwood Pharmaceuticals
  86. 6.15.1 Ironwood Pharmaceuticals Company Information
  87. 6.15.2 Ironwood Pharmaceuticals Business Overview
  88. 6.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
  90. 6.15.5 Ironwood Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Sickle Cell Anemia Therapeutics Market Size (2021-2032)
  2. 7.2 North America Sickle Cell Anemia Therapeutics Market Size by Type
  3. 7.2.1 North America Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Sickle Cell Anemia Therapeutics Market Size by Application
  7. 7.3.1 North America Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Sickle Cell Anemia Therapeutics Market Size by Country
  11. 7.4.1 North America Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Sickle Cell Anemia Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Sickle Cell Anemia Therapeutics Market Size by Type
  3. 8.2.1 Europe Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Sickle Cell Anemia Therapeutics Market Size by Application
  7. 8.3.1 Europe Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Sickle Cell Anemia Therapeutics Market Size by Country
  11. 8.4.1 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Sickle Cell Anemia Therapeutics Market Size (2021-2032)
  2. 9.2 China Sickle Cell Anemia Therapeutics Market Size by Type
  3. 9.2.1 China Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Sickle Cell Anemia Therapeutics Market Size by Application
  7. 9.3.1 China Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Sickle Cell Anemia Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Sickle Cell Anemia Therapeutics Market Size by Type
  3. 10.2.1 Asia Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Sickle Cell Anemia Therapeutics Market Size by Application
  7. 10.3.1 Asia Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Sickle Cell Anemia Therapeutics Market Size by Country
  11. 10.4.1 Asia Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst